Featured Press Releases

Niagen Bioscience announces that pharmaceutical-grade Niagen® IV is now available in nearly 600 clinics nationwide.

Niagen Bioscience announces that pharmaceutical-grade Niagen® IV is now available in nearly 600 clinics nationwide.

SciTech Development announces the second FDA approval of a Phase 1 A/B IND for ST-001, which now targets the treatment of relapsed/refractory small cell lung cancer, following its previous approval for the treatment of T-cell NHL

SciTech Development announces the second FDA approval of a Phase 1 A/B IND for ST-001, which now targets the treatment of relapsed/refractory small cell lung cancer, following its previous approval for the treatment of T-cell NHL

  • 08 Apr 2025

SciTech Development, Inc., a clinical-stage oncology company pioneering innovative cancer...

GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.

GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.

Nuvation Bio unveils new data on IBTROZI™ (taletrectinib) in advanced ROS1-positive non-small cell lung cancer

Nuvation Bio unveils new data on IBTROZI™ (taletrectinib) in advanced ROS1-positive non-small cell lung cancer

Fzata secures a clinical trial agreement for FZ002, targeting C. difficile treatment.

Fzata secures a clinical trial agreement for FZ002, targeting C. difficile treatment.

Hologic’s Aptima® HPV Test Receives Expanded CE-IVDR Mark to Include Self-Collected Samples for Cervical Cancer Screening

Hologic’s Aptima® HPV Test Receives Expanded CE-IVDR Mark to Include Self-Collected Samples for Cervical Cancer Screening

ImmunoScape Appoints Peter Olagunju as Chief Executive Officer

ImmunoScape Appoints Peter Olagunju as Chief Executive Officer

  • ImmunoScape Pte. Ltd.
  • 23 Sep 2026
LEVEL Relief Protab Reduced Everyday Aches and Pain in an Independent 29-Day Study

LEVEL Relief Protab Reduced Everyday Aches and Pain in an Independent 29-Day Study

  • LEVEL
  • 22 Sep 2026
FDA Updates WINREVAIR™ Label with HYPERION Phase 3 Trial Data in Adults Newly Diagnosed with PAH

FDA Updates WINREVAIR™ Label with HYPERION Phase 3 Trial Data in Adults Newly Diagnosed with PAH

  • Merck & Co., Inc.
  • 22 Sep 2026
Padagis Expands Workplace Naloxone Access by Providing Free Nasal Sprays to Qualifying Businesses

Padagis Expands Workplace Naloxone Access by Providing Free Nasal Sprays to Qualifying Businesses

  • Padagis
  • 21 Sep 2026
StimCardio’s NeuroPulse Study Reports a Substantial Reduction in Recurrent Atrial Fibrillation Events Following Ablation Using Non-Invasive Wearable Neuromodulation

StimCardio’s NeuroPulse Study Reports a Substantial Reduction in Recurrent Atrial Fibrillation Events Following Ablation Using Non-Invasive Wearable Neuromodulation

  • StimCardio’s
  • 21 Sep 2026
Bruker Receives Order for High-Field NMR Systems to Support a Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley.

Bruker Receives Order for High-Field NMR Systems to Support a Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley.

  • Bruker Corporation
  • 21 Sep 2026

Most Popular
September   2026
M T W T F S S
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30        

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.